Allison DeAngelis from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago
2	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago
3	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 3 months ago
4	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 17 days ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 24 days ago STAT+: Seaport Therapeutics adds another $225 million to coffers to embrace the ‘golden age of neuroscience’ - 28 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago Biotech veteran Tony Coles on partisan politics and fulfilling a promise to his co-founder - about 1 month ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - about 2 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 2 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 2 months ago STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance - 2 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 3 months ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 3 months ago STAT+: AI drug firm Recursion seeks to move from survival to industry domination - 3 months ago Listen: Drug pricing drops & psychedelics under fire - 3 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 4 months ago STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies - 4 months ago STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund - 4 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 4 months ago STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 6 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 6 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 7 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 7 months ago STAT+: Biotech startups post strongest financing numbers in two years - 7 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 8 months ago STAT+: Investors funnel $275 million into Paragon Therapeutics spinout - 8 months ago STAT+: As AI proliferates, biopharma companies seek to harness it in clinical trials - 8 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 8 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 8 months ago Listen: Live! From the STAT Breakthrough Summit East - 8 months ago STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO - 8 months ago STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline - 8 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 8 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 9 months ago STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - 9 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 9 months ago STAT+: Biotech launches with $82 million for Parkinson’s cell therapy - 9 months ago Q&A: A biotech VC leader shares her next big bets - 9 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 9 months ago STAT+: Flagship Pioneering startup lays off a third of staff - 9 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 9 months ago STAT+: Biotech launches with $135 million for Vertex-competing pain medicine - 9 months ago STAT+: Startup BioAge raises $170 million Series D for Zepbound combination therapy - 9 months ago Listen: AI in medicine, detangling hype, and Icelandic DNA - 9 months ago STAT+: Eli Lilly reports tirzepatide MASH success during Q4 earnings - 10 months ago Listen: The plight of the VC, Gilead’s latest setback, & more M&A - 10 months ago Biotech layoffs, slumping stocks, and a 2024 preview - 10 months ago STAT Virtual Event \| 2024 JPM Recap, Live! - 10 months ago The highs — and lows — of JPM 2024 you should pay attention to - 10 months ago Listen: Live! From JPM 2024 - 10 months ago
5	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago The highs — and lows — of JPM 2024 you should pay attention to - 10 months ago
6	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 17 days ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 24 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - about 2 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 2 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 2 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 3 months ago Listen: Drug pricing drops & psychedelics under fire - 3 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 4 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 4 months ago
7	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 17 days ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 24 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - about 2 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 2 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 3 months ago Listen: Drug pricing drops & psychedelics under fire - 3 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 4 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 4 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 6 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 7 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 7 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 8 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 8 months ago Listen: Live! From the STAT Breakthrough Summit East - 8 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 8 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 9 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 9 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 9 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 9 months ago Listen: AI in medicine, detangling hype, and Icelandic DNA - 9 months ago Listen: The plight of the VC, Gilead’s latest setback, & more M&A - 10 months ago Biotech layoffs, slumping stocks, and a 2024 preview - 10 months ago The highs — and lows — of JPM 2024 you should pay attention to - 10 months ago Listen: Live! From JPM 2024 - 10 months ago
8	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 7 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 8 months ago Listen: Live! From the STAT Breakthrough Summit East - 8 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 8 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 9 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 9 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 9 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 9 months ago Listen: AI in medicine, detangling hype, and Icelandic DNA - 9 months ago Listen: The plight of the VC, Gilead’s latest setback, & more M&A - 10 months ago Biotech layoffs, slumping stocks, and a 2024 preview - 10 months ago The highs — and lows — of JPM 2024 you should pay attention to - 10 months ago Listen: Live! From JPM 2024 - 10 months ago
9	Mario Aguilar STAT News Reporter at STATnews. Previous engagements noted. Personal views. Brooklyn techhealth care	STAT+: How biotech investors spot opportunity when stocks are down — and up - 8 months ago